Show Summary Details

Page of

PRINTED FROM OXFORD HANDBOOKS ONLINE (www.oxfordhandbooks.com). © Oxford University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 October 2018

Abstract and Keywords

Neuroethical issues in the early detection of Alzheimer's disease (AD) are likely to be characteristic of any disorder where the boundary conditions between being impaired and unimpaired are unclear. Initial research efforts were focused on examining patients with established disease. The article discusses some challenges for the clinical diagnosis of mild cognitive impairment. The overarching ethical concern is that the term mild cognitive impairment (MCI) is being applied to patients in clinical settings, when the majority of the data pertains to risk for groups of subjects, as opposed to individuals. These same challenges regarding the boundary between normal and abnormal, and the probabilistic nature of predicting progression, apply to individuals with normal cognition. This balance between risks and benefits would, of course, change, when disease-modifying therapies are identified. Then potentially beneficial treatments could be instituted even when someone is cognitively normal.

Keywords: neuroethical issues, mild cognitive impairment, Alzheimer's disease, disease-modifying therapies, clinical settings

Access to the complete content on Oxford Handbooks Online requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.